

Opioid Use Disorder Examinations and Treatment

Data Definitions and Reporting Guide

This *Opioid Use Disorder Examinations and Treatment: Data Definitions and Reporting Guide* provides guidance on the submission of opioid use disorder screening, evaluation, and treatment program information, as required by House Bill 116 (2019). Created with input from stakeholders, this guide serves to identify the reporting requirements, a definition for required data elements, and instructions on the submission of all opioid use disorder screening, evaluation, and treatment program information. **To quickly access one of these areas, please select from the following list.**

Introduction	2
Data Definitions	3
Reporting Period	4
Reporting Guide	4
(MOUD) Treatment Data Entry	4
Annual Cost Assessment	10

Introduction

House Bill 116 (2019) established programs for opioid use disorder screening, evaluation, and treatment (specifically medications to treat opioid use disorder (MOUD)) in local correctional facilities and in the Baltimore Pretrial Complex.¹ It also required the program to begin in four counties (Howard, Montgomery, Prince George's, and St. Mary's) by January 1, 2020, apply to six additional counties by October 1, 2021, and then expand to include all counties and the Baltimore Pretrial Complex by January 2023. In addition, the Act requires the State to fund the programs, and it establishes requirements for screening and treatment. Furthermore, and in accordance with § 9-603(j) of the Correctional Services Article, the Governor's Office of Crime Prevention and Policy (Office) shall report data from individual local correctional facilities to the General Assembly by November 1, 2020, and annually thereafter, as it relates to the following:

1. The number of incarcerated individuals diagnosed with:
 - a. A mental health disorder;
 - b. An opioid use disorder;
 - c. A non-opioid substance use disorder; and
 - d. A dual diagnosis of mental health and substance use disorder;
2. The number and cost of assessments for incarcerated individuals in local correctional facilities, including the number of unique incarcerated individuals examined;
3. The number of incarcerated individuals who were receiving medication or MOUD for opioid use disorder immediately prior to incarceration;
4. The type and prevalence of medication or MOUD for opioid use disorder provided;
5. The number of incarcerated individuals for whom medication and MOUD for opioid use disorder was prescribed;
6. The number of incarcerated individuals for whom medication and MOUD was prescribed and initiated for opioid use disorder;
7. The number of incarcerated individuals who continued to receive the same medication or MOUD for opioid use disorder as the incarcerated individual received prior to incarceration;
8. The number of incarcerated individuals who received a different medication or MOUD for opioid use disorder compared to what the incarcerated individual received prior to incarceration;
9. The number of incarcerated individuals who discontinued medication or MOUD for opioid use disorder during incarceration;

¹ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment*](#). Maryland Department of Legislative Services. (2019). [*The 90 Day Report: A Review of the 2019 Legislative Session*](#).

10. A review and summary of the percent of days, including the average percent, median percent, mode percent, and interquartile range of percent, for incarcerated individuals with opioid use disorder receiving medication or MOUD for opioid use disorder as calculated overall and stratified by other factors, such as type of treatment received;
11. The number of incarcerated individuals receiving medication or MOUD prior to release for whom the facility had made a pre-release reentry plan;
12. A review and summary of practices related to medication and MOUD for opioid use disorder for incarcerated individuals with opioid use disorder before October 1, 2019;
13. A review and summary of pre-release planning practices relative to incarcerated individuals diagnosed with opioid use disorder prior to, and following, October 1, 2019; and
14. Any other information requested by the Maryland Department of Health related to the administration of the provisions under this section.

Data Definitions

The following definitions must be used when submitting opioid use disorder screening, evaluation, and treatment program information:

Assessment means any in-depth, evidence-based screening performed by a specified health care practitioner on an individual for diagnostic purposes.

Incarcerated individual or **incarceree** (previously “inmate²”) means an individual confined within a local correctional facility.³

Medication means a medication approved by the federal Food and Drug Administration for the treatment of opioid use disorder.⁴

Medications for Opioid Use Disorder (MOUD) (also known as medication-assisted treatment, or MAT) means the use of medication, in combination with counseling and behavioral health therapies, to provide a holistic approach to the treatment of opioid use disorder.⁵

² It should be noted that § 9-603(j) of the Correctional Services Article now uses the term “incarcerated individual” to refer to individuals confined within a local correctional facility. Certain documents pertaining to the original bill and referenced in this document may use the term “inmate;” however, both refer to the same population.

³ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment*](#).

⁴ Ibid.

⁵ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment \(Fiscal and Policy Note\)*](#).

Opioid use disorder means a medically diagnosed problematic pattern of opioid use that causes significant impairment or distress.⁶

Peer recovery specialist means an individual who has been certified by an entity approved by the Maryland Department of Health for the purpose of providing peer support services, as defined under § 7.5-101(n) of the Health - General Article.⁷

Reporting Period

All jails must compile and submit their data in the described format (see below) no later than August 1 of each year, to cover the reporting period of the prior State fiscal year (July 1 - June 30). Because the data is requested per individual, in order to follow their movement through the program, all data entries should occur on an ongoing basis.

Reporting Guide

All opioid use disorder screening, evaluation, and treatment program information can be entered into an excel spreadsheet template which includes data elements required by [House Bill 116 \(2019\)](#). A description of the data elements, to include the available selections for each, is provided below. It is important to note there are **two** sheets to enter data on: the first sheet, named “Data Entry” includes all data elements outlined in the statute above, except for cost-related data. The second sheet, named “Annual Cost Assessment” includes the cost-related data for implementing MOUD programs within correctional facilities.

(MOUD) Treatment Data Entry

The first sheet in the template, “(MOUD) Treatment Data Entry,” is dedicated to capturing data element #1 through data element #11, as listed in the Introduction section above.

#1. The number of incarcerated individuals diagnosed with: a mental health disorder; an opioid use disorder; a non-opioid substance use disorder; and a dual diagnosis of mental health and substance use disorder.⁸

The template will designate four columns to capture this data element, to include the following:

⁶ Ibid.

⁷ Maryland General Assembly. (2019). [House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment](#).

⁸ Dual Diagnosis means that the individual *must* have a mental health disorder diagnosis in addition to a substance use disorder diagnosis. The substance use disorder diagnosis may consist of either an opioid use disorder, a non-opioid substance use disorder, or both.

ID#: A unique identifier must be provided for each incarcerated individual who has been diagnosed with a mental health disorder, an opioid use disorder, a non-opioid substance use disorder, and a dual diagnosis of mental health and substance use disorder. Do not use simple indexing (e.g., #1, #2, #3) as an ID# as this is not a sufficiently unique identifier. If an incarcerated individual is diagnosed multiple times during the reporting period, and/or if the diagnosis changes, include the same ID# as their first diagnosis. This information will be used to track the total number of incarcerated individuals diagnosed and the total number of diagnoses. Please note that all incarcerated individuals diagnosed with one of the items listed above must be accounted for.

Opioid Use Disorder: If an incarcerated individual is diagnosed with an *Opioid use disorder* either by itself or with an accompanying diagnosis, use the “dropdown” menu to select the presence of an opioid use disorder.

- Yes
- No

Non-Opioid Substance Use Disorder: If an incarcerated individual is diagnosed with an *Non-opioid substance use disorder* is selected for the diagnosis, either by itself or with an accompanying diagnosis, use the “dropdown” menu to select the presence of a non-opioid substance use disorder. It is important to note that if a non-opioid substance use disorder is entered and there is no presence or diagnosis of an opioid use disorder, **no additional information is necessary for the remaining data elements (i.e., data element #2 through data element #11) for this incarcerated individual.**

- Yes
- No

Mental Health Disorder: If an incarcerated individual is diagnosed with an *Mental health disorder*, either by itself or with an accompanying diagnosis, use the “dropdown” menu to select the presence of a mental health disorder. It is important to note that if a mental health disorder is entered and there is no presence or diagnosis of an opioid use disorder, **no additional information is necessary for the remaining data elements (i.e. data element #2 through data element #11) for this incarcerated individual.**

- Yes
- No

Please note that *dual diagnosis* does not have a dedicated column to capture data. This data point will be calculated by the Office based on responses for the prior three columns: *opioid use disorder*, *non-opioid substance use disorder*, and *mental health disorder*.

#2. The number and cost of assessments for incarcerated individuals in local correctional facilities, including the number of unique incarcerated individuals examined.

The template will designate one column to capture this data element, to include the following:

Assessments: Provide the number of assessments for each incarcerated individual.⁹ If an incarcerated individual is assessed multiple times during the reporting period, include the same ID# as their first assessment. This information will be used to track the total number of incarcerated individuals assessed and the total number of assessments.

Please note that applicable information relating to the cost of assessments (e.g, mental health assessments, opioid screening, medical screening, etc.) is described in the next section of this guide, Sheet 2: Annual Cost Assessment.

#3. The number of incarcerated individuals who were receiving medication or MOUD for opioid use disorder immediately prior to incarceration.

The template will designate one column to capture this data element, to include the following:

Treatment prior to incarceration: Use the “dropdown” menu to select if the incarcerated individual was receiving medication or MOUD for opioid use disorder immediately prior to incarceration. By selecting *Yes*, this indicates that the incarcerated individual was receiving medication or MOUD at the time of their placement in jail and/or 30 days prior to incarceration.

- Yes
- No

⁹ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment \(Fiscal and Policy Note\)*](#). The fiscal note provides the following definition for screening: “Each local correctional facility must conduct an assessment of the mental health and substance use status of each inmate using evidence-based screenings and assessments to determine if the medical diagnosis of an opioid use disorder is appropriate and if MAT is appropriate. If a required assessment indicates opioid use disorder, an evaluation of the inmate must be conducted by a specified health care practitioner; and information must be provided to the inmate describing medications used in MAT. In addition, MAT must be available to an inmate for whom such treatment is determined to be appropriate, as specified.”

Please note that [House Bill 116 \(2019\)](#) does not specify a timeframe for *immediately*. Because of this, and for the purpose of data entry, the term *immediately* refers to *within the past 30 days prior to incarceration*.

#4. The type and prevalence of medication or MOUD for opioid use disorder provided.

The template will designate four columns to capture this data element, to include the following:

Type of treatment: Use the “dropdown” menu to select the type of treatment for opioid use disorder.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine
- Other
- None, incarcerated declined
- None, incarcerated released prior to receiving program services

Other: If *Other* is selected for the type of treatment, write out the applicable type.

Route of administration: Use the “dropdown” menu to select the route of administration. Please refer to the [Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning & Implementation Toolkit](#) (pages 12-13) and [Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System](#) (page 15) for more information.

- Oral
- Injection

Frequency of administration: Use the “dropdown” menu to select the frequency in which the medication or MOUD is administered.

- Daily
- Monthly

#5. The number of incarcerated individuals for whom medication and MOUD for opioid use disorder was prescribed.

The template will designate one column to capture this data element, to include the following:

Prescribed treatment: Use the “dropdown” menu to select if the incarcerated individual was prescribed medication or MOUD for opioid use disorder. Please note that all incarcerated individuals prescribed treatment for opioid use disorder at intake must be accounted for.

- Yes
- No

#6. The number of incarcerated individuals for whom medication and MOUD was prescribed and initiated for opioid use disorder.

The template will designate one column to capture this data element, to include the following:

Initiated treatment: Use the “dropdown” menu to select if medication and MOUD was initiated by the incarcerated individual.

- Yes
- No
- Not applicable (if no was selected in #5)

#7. The number of incarcerated individuals who continued to receive the same medication or MOUD for opioid use disorder as the incarcerated individual received prior to incarceration.

The template will designate one column to capture this data element, to include the following:

Continued same treatment: Use the “dropdown” menu to select if the incarcerated individual continued to receive the same medication or MOUD as they received prior to incarceration.

- Yes
- No
- Not applicable

#8. The number of incarcerated individuals who received a different medication or MOUD for opioid use disorder compared to what the incarcerated individual received prior to incarceration.

The template will designate one column to capture this data element, to include the following:

Received different treatment: Use the “dropdown” menu to select if the incarcerated individual received a different medication or MOUD as they received prior to incarceration.

- Yes
- No
- Not applicable

#9. The number of incarcerated individuals who discontinued medication or MOUD for opioid use disorder during incarceration.

The template will designate one column to capture this data element, to include the following:

Discontinued treatment: Use the “dropdown” menu to select if the incarcerated individual discontinued treatment during incarceration.

- Yes, voluntary
- Yes, involuntary
- Yes, unknown
- No
- Not applicable

Please note that incarcerated individuals who continue, discontinue, and/or re-start medication or MOUD for opioid use disorder will be captured based on their ID#.

#10. A review and summary of the percent of days, including the average percent, median percent, mode percent, and interquartile range of percent, for incarcerated individuals with opioid use disorder receiving medication or MOUD for opioid use disorder as calculated overall and stratified by other factors, such as type of treatment received.

The template will designate four columns to capture this data element, to include the following:

Intake date: Provide the date in which the incarcerated individual entered the jail, based on a MM/DD/YYYY format.

Treatment start date: Provide the date in which the treatment started, based on a MM/DD/YYYY format. This represents the date in which the incarcerated individual received their first dose.

Release date: Provide the date in which the incarcerated individual was released from the facility, based on a MM/DD/YYYY format. Leave blank if the incarcerated individual is still incarcerated.

Treatment end date: Provide the date in which the treatment ended, based on a MM/DD/YYYY format. Leave blank if the incarcerated individual is still in treatment.

#11. The number of incarcerated individuals receiving medication or MOUD prior to release for whom the facility had made a pre-release reentry plan.

The template will designate one column to capture this data element, to include the following:

Reentry plan: Use the “dropdown” menu to select if the incarcerated individual received a pre-release reentry plan.

- Yes
- No
- Not applicable

For incarcerated individuals who receive more than one treatment during one period of stay, this selection should reflect their most recent treatment

Annual Cost Assessment

The second sheet in the template, “Annual Cost Assessment,” is dedicated to capturing the cost-related data of implementing MOUD programs in correctional facilities.

#2. The number and cost of assessments for incarcerated individuals in local correctional facilities, including the number of unique incarcerated individuals examined.

There are three subsections to capture cost-related data: Medications, Drug Screenings, and Miscellaneous, each of which are listed below.

Medications

The template will designate four columns to capture this data element, to include the following:

Incarcerees: Provide the number of individuals receiving medication or MOUD for each treatment type, listed below.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine
- Other

Monthly: Provide the average monthly cost of medication or MOUD for one individual for each treatment type, listed below.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine

- Other

Annual: Provide the average annual cost of medication or MOUD for one individual for each treatment type, listed below.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine
- Other

Total: Provide the total cost of medication or MOUD for all individuals for each treatment type, listed below.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine
- Other

Drug Screenings

The template will designate four columns to capture this data element, to include the following:

Number: Provide the total number of drug screenings administered for each screening type, listed below.

- Urinalysis Drug Tests (In-House)
- Urinalysis Drug Tests (Outsourced)

Monthly: Provide the average monthly cost of administering each type of drug screening, listed below.

- Urinalysis Drug Tests (In-House)
- Urinalysis Drug Tests (Outsourced)

Annual: Provide the average annual cost of administering each type of drug screening, listed below.

- Urinalysis Drug Tests (In-House)
- Urinalysis Drug Tests (Outsourced)

Total: Provide the total cost of administering each type of drug screening for each screening type, listed below.

- Urinalysis Drug Tests (In-House)

- Urinalysis Drug Tests (Outsourced)

Miscellaneous

The template will designate one column to capture this data element, to include the following:

Total: Provide the total cost for relevant staffing, listed below.

- Registered Nurse
- Substance Use Counselor
- Peer Recovery Specialist